Commentary by Josh Remick MD, PGY-3
Hypertriglyceridemia is defined by the NCEP guidelines for treatment as a fasting triglyceride level greater than 200 mg/dL after the target LDL-C level has been achieved (1). When triglyceride levels …
Clinical Correlations
The NYU Langone Health Online Journal of Medicine
ShortCuts-This Week in the Journals
October 29, 2007
Commentary by Michael Poles MD, Associate Editor, Clinical Correlations
This week seems like a continuation of last week in a couple of ways. Last week our Editor-In-Chief, Dr. Neil Shapiro, wrote about the …
Inpatient Diabetes Management: Case 5
October 25, 2007
Commentary by Mary Vouyiouklis MD, Fellow, and Ann Danoff MD, Director, Division of Endocrinology, Diabetes and Metabolism, NYU Medical Center
Welcome to Case 5 of our special diabetes series intended to highlight the essentials …
FDA Approves Label Revision for Erectile Dysfunction Drugs
October 24, 2007
Commentary by Kathy Lee, Pharm.D. Pharmacy Practice Resident
On October 18 2007, the FDA announced the approval of labeling changes to erectile dysfunction (ED) drugs in the class known as phosphodiesterase type 5 (PDE-5) …
ShortCuts-This Week in the Journals
October 22, 2007Commentary by Neil Shapiro MD, Editor-In-Chief, Clinical Correlations
As fall begins in earnest and the leaves start to change we find a diverse group of articles that make the cut and a few that didn’t quite make it …
Clinical Pathology Conference 10/12/07-The Answer
October 19, 2007Case Presentation by Elizabeth Ross, MD, Chief Resident
Please review the posting of last week’s CPC here.
When you’re ready you can download the CPC Answer.
Class Act: Relieving the Obstruction – Surgical Approaches to the Management of Obstructive Sleep Apnea
October 18, 2007
Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. These posts focus on evidenced based answers to clinical questions related to patients seen by …
Clinical Pharmacy Corner: How Do Sulfonylureas Work?
October 17, 2007Commentary by Helen Kourlas, PharmD and John Papadopoulas, PharmD, Pharmacology Section Editors
The sulfonylureas are members of a class of substituted arylsulfonylureas that have been used clinically since the 1950s. These agents are usually divided into two categories or generations. First generation agents include acetohexamide, chlorpropamide, tolazamide, and tolbutamide (the …